Vasopressin

Vasopressin, also known as antidiuretic hormone (ADH) and arginine vasopressin (AVP), is a hormone secreted by most mammals, including humans. It functions primarily to help the body regulate and retain water and constrict blood vessels. It plays a role in helping the body stay hydrated and keep blood pressure under control. Early twenty-first-century research also indicates that vasopressin may affect the brain and could affect social skills related to autism and in how animals bond.

A synthetic version of vasopressin is available and marketed in injectable and nasal spray forms. These versions are administered for a variety of medical conditions, including diabetic insipidus, some bleeding disorders, severe childhood bed-wetting, and septic shock.

Production and Function

Vasopressin’s hormonal form is a polypeptide (a chain of amino acids) produced by the hypothalamus. It moves from the hypothalamus to the pituitary gland to be released as needed.

Vasopressin is an antidiuretic, which means it prevents the body from losing water through urination. Its production is triggered by neurons called osmoreceptors, located in the hypothalamus. The osmoreceptors detect the amount of solutes, such as plasma and other organic components, present in the blood. When the osmoreceptors determine that solutes are becoming concentrated—such as when the body is losing fluid due to profuse sweating—they signal the hypothalamus to release vasopressin and prevent the loss of more fluids through urination. The hormone is sent to the kidneys, where it helps to create small channels that send solute-free water back into the bloodstream to dilute the solutes in the blood while reducing the amount of urine and increasing its concentration.

Retaining fluids in this way can be important because the osmoreceptors that cause thirst are not as sensitive as those that prevent urination. Humans, who are about 60 percent water by mass on average, can become dehydrated before feeling thirsty, and vasopressin helps in conserving necessary fluids to maintain relatively stable water content levels.

Although vasopressin’s most significant function is in preventing excessive water loss through urination, it is actually named for its effects on the body’s vascular system. While its effect on the human circulatory system is relatively minor, high levels of vasopressin can have a significant effect on blood pressure in other mammals. Decreases in blood pressure or blood volume can stimulate the release of vasopressin, which can constrict blood vessels. Significant blood loss, including losses around 15 to 20 percent of blood volume, can trigger the release of vasopressin in mammals, including humans.

Sometimes the body’s ability to produce vasopressin is affected by damage to the pituitary gland or hypothalamus resulting from a head injury, infection, tumor, surgery, loss of blood flow to the gland, or a genetic problem. Impaired vasopressin production can lead to a condition called central diabetes insipidus. Characterized by extreme thirst that generates excessive urine output—as high as 16 liters (approximately 4.25 gallons) in a single day—central diabetes insipidus is not common and is not often life-threatening, assuming adequate amounts of water are available for consumption. The condition is treated through the administration of synthetic vasopressin.

Pharmaceutical Uses

In addition to treating central diabetes insipidus, the synthetic form of vasopressin can be used for a number of other conditions. The synthetic form has been used to help manage abdominal distension following surgery, to treat conditions such as diabetes insipidus, and to manage certain types of shock and bleeding from esophageal varices. It also is used during abdominal roentgenography—an X-ray imaging procedure to diagnose problems in the liver, spleen, gallbladder, and other abdominal organs—to reduce interference from gas shadows. Because the synthetic vasopressin restricts urine production, it has also been used to treat extreme instances of juvenile bed-wetting.

Continuing Research

In the early twenty-first century, researchers began making connections between vasopressin and social behavior. Studies on the connection between two similar hormones, vasopressin and oxytocin, have indicated that some brain receptors react to both hormones. Oxytocin is generally associated with the generation of good feelings and happiness, while vasopressin appears to be linked to aggression and anxiety. Animal studies have indicated that males are more susceptible to responding with aggression when high levels of vasopressin are present. Some studies have indicated that vasopressin is linked to how mammals process sensory input such as sounds and smells.

These connections led researchers to look at vasopressin’s possible role in autism, a condition whose effects can include behavioral issues. According to the National Institute of Mental Health, Autism Spectrum Disorder (ASD) affected about one in every thirty-six American children based on 2020 data reported in 2023. In one study, researchers from Stanford University concluded that the presence of vasopressin at certain levels could predict how children with autism would perform on a test that measured their perception of the perspectives of other people. Autistic children with low levels of vasopressin did not score well on this test; children without autism and with low vasopressin levels showed no difference in scoring.

A pilot study conducted in 2019 by researchers at Stanford University tested the effects of intranasal vasopressin on social behavior in children with autism. This trial marked the first of its kind. The study involved thirty children aged six to twelve and found that vasopressin improved social behaviors, reduced anxiety, and lessened repetitive behaviors compared to a placebo. Parents’ and researchers’ ratings of social abilities and lab tests supported the study’s findings. A Phase 2/3 clinical trial involving 157 participants was completed in 2024 to evaluate intranasal vasopressin as a treatment for autism spectrum disorder. The researchers discovered that children with higher baseline vasopressin levels showed the greatest improvement in social abilities and anxiety. These results suggest that vasopressin may influence social behavior in autism, but further large trials are needed to confirm the study’s findings. A 2026 study found that lower cerebrospinal fluid vasopressin levels were associated with greater social impairment in children with autism, indicating its potential as a biomarker, but more research is needed to confirm these findings.

Another study, conducted by researchers at the University of Queensland in Australia, looked at behavior patterns and vasopressin levels of almost 7,400 twins from Finland and their siblings. The researchers examined the relationships of these twins and their partners, all of whom had been in relationships with a partner for at least one year. Their work indicated a connection between a variation in the gene for a vasopressin receptor and infidelity. The study received great attention and was touted as an indicator that infidelity in a relationship may have a genetic cause, but the researchers urged caution in interpreting the results and suggested that much more study was required.

Bibliography

“Arginine Vasopressin, Plasma.” Mayo Clinic Laboratories, 18 Apr. 2019, www.mayocliniclabs.com/test-notifications/attachment.php?id=58656. Accessed 4 Apr. 2026.

“Autism Spectrum Disorder.” National Institute of Mental Health, July 2025, www.nimh.nih.gov/health/statistics/autism-spectrum-disorder-asd. Accessed 4 Apr. 2026.

“Diabetes Insipidus.” MedlinePlus, U.S. National Library of Medicine, 22 Nov. 2016, www.nlm.nih.gov/medlineplus/diabetesinsipidus.html. Accessed 4 Apr. 2026.

Digitale, Erin. “Hormone Reduces Social Impairment in Kids with Autism.” Stanford Medicine News Center, 1 May 2019, med.stanford.edu/news/all-news/2019/05/hormone-reduces-social-impairment-in-kids-with-autism.html. Accessed 4 Apr. 2026.

“Infidelity Lurks in Our Genes.” International Andrology London, 2021, london-andrology.co.uk/news/infidelity-lurks-in-our-genes/. Accessed 4 Apr. 2026.

Klabunde, Kevin. “Vasopressin (Antidiuretic Hormone).” Cardiovascular Physiology Concepts, 8 Dec. 2022, cvphysiology.com/blood-pressure/bp016. Accessed 4 Apr. 2026.

Landau, Elizabeth. “Vasopressin Emerges as Hormone of Interest in Autism Research.” Scientific American, 11 Sept. 2015, www.scientificamerican.com/article/vasopressin-emerges-as-hormone-of-interest-in-autism-research/. Accessed 4 Apr. 2026.

“Study of Intranasal Vasopressin in Children with Autism Spectrum Disorder.” ClinicalTrials.gov, U.S. National Library of Medicine, 2025, clinicaltrials.gov/study/NCT03204786. Accessed 4 Apr. 2026.

Valenti, Giovanna, and Grazia Tamma. “Chapter 18 – The vasopressin–aquaporin-2 pathway syndromes.” The Handbook of Clinical Neurology, vol. 118, 2021, pp. 249–59, doi:10.1016/B978-0-12-820683-6.00018-X. Accessed 4 Apr. 2026.

“Vasopressin (Injection Route).” Mayo Clinic, 1 Feb. 2026, www.mayoclinic.org/drugs-supplements/vasopressin-injection-route/description/DRG-20066681. Accessed 4 Apr. 2026.

Zietsch, Brendan P., et al. “Genetic Analysis of Human Extrapair Mating, Heritability, Between-Sex Correlation, and Receptor Genes for Vasopressin and Oxytocin.” Evolution and Human Behavior, vol. 36, no. 2, March 2015, pp. 130–36, doi:10.1016/j.evolhumbehav.2014.10.001. Accessed 4 Apr. 2026.